Taiyu Investment
VC Fund
Beijing, China
Taiyu Investment is an investment firm.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 6%
Last updated:
For AI agents: llms.txt
Industries Taiyu Investment invests in
Stages Taiyu Investment invests in
Countries Taiyu Investment invests in
Round sizes
Round size
- Seed
- $2.8M–$20M
- Angel
- $434k–$451k
- Series A
- $13M–$16M
Investment Focus
Industry
- Medical 10 (59%)
- Health Care 8 (47%)
- Biotechnology 5 (29%)
- Medical Device 4 (24%)
- Biopharma 2 (12%)
Stage
- Series A 6 (35%)
- Seed 4 (24%)
- Angel 3 (18%)
- Series C 2 (12%)
- Series B 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Weixin Medical
|
Weixin Medical is an innovative medical device platform for women's health. | Series A / Jul 10, 2023 | |
| ChomiX Biotech will always manage the company's development with a realistic, disciplined, and excellence-driven scientific research mindset. In addition, the company will use cutting-edge technology to solve problems for clients and generate revenue. We can only see the stars if we stay grounded. ChomiX will continue to research and developits own core technology in order to continually maintain its top rank on the track and steer the development of the industry. | Seed / May 15, 2023 | ||
Immorna
|
Immorna specializes in the production of RNA-based therapeutics. | $13M / Series A / Feb 27, 2023 | |
| Leadino Medical Valley is a producer of medical devices for neuroregulatory functions. | $14.4M / Series A / Sep 09, 2022 | ||
Epigenic Therapeutics
|
Epigenic Therapeutics is a biotech firm that offers gene editing therapy. | $20M / Seed / Aug 06, 2022 | |
| TINGSN develops Intracardiac echocardiography (ICE) catheter imaging technology designed to treat cardiac arrhythmia. In addition to ICE products, the company has developed its own heart internal catheter positioning and software algorithms and is developing China first computer surgical simulator for cardiac electrophysiology based on digitalheart model. | $15.8M / Series A / Mar 03, 2022 | ||
| Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research. | Series A / Jan 11, 2022 | ||
| Hesguard is a medical device developer and producer of high-end implantable medical devices related to ophthalmic diseases. | $15.7M / Seed / Dec 26, 2021 | ||
| Hangzhou DAC Biotech Co., Ltd focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drugs. | $154.9M / Series C / May 12, 2021 | ||
Novamab
|
Novamab focuses on the research and development of new nanobodies. The core members of the team have 15 years of experience in nanobody research and development, and are domestic nanobody "pioneers". At present, they have established an inhaled macromolecular drug research and development platform, an albumin nanobody long-acting platformand a nanobody double-antibody platform, etc., to give full play to nanobody The advantages of antibodies, the development of innovative nanobody drugs such as sprays and eye drops, to solve the pain points of clinical major chronic diseases in terms of administration methods, administration cycles, etc. | $15.4M / Series A / Mar 12, 2021 | |
| See all 17 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Taiyu Investment invest in?
Taiyu Investment invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 17 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Taiyu Investment's check size?
Taiyu Investment typically joins rounds of $2.8M–$20M at Seed, $434k–$451k at Angel and $13M–$16M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Taiyu Investment participates in.
When did Taiyu Investment last invest?
The most recent investment recorded for Taiyu Investment closed in Jul 2023. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
